Vor Biopharma Inc VOR.OQ VOR.O is expected to show no change in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Vor Biopharma Inc is for a loss of $3.34 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Vor Biopharma Inc is $57.50, about 58.1% above its last closing price of $24.11
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -10.90 | -8.77 | -43.80 | Missed | -399.5 |
Mar. 31 2025 | -4.42 | -4.57 | -5.20 | Missed | -13.8 |
Dec. 31 2024 | -4.35 | -5.71 | -8.80 | Missed | -54 |
Sep. 30 2024 | -8.14 | -8.04 | -8.00 | Beat | 0.5 |
Jun. 30 2024 | -8.42 | -8.36 | -8.20 | Beat | 1.9 |
Mar. 31 2024 | -7.63 | -7.57 | -9.00 | Missed | -18.9 |
Dec. 31 2023 | -10.40 | -10.07 | -7.80 | Beat | 22.5 |
Sep. 30 2023 | -9.39 | -9.37 | -9.80 | Missed | -4.6 |
This summary was machine generated November 3 at 11:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)